According to GuruFocus Insider Data, these are the largest CFO buys during the past week. The overall trend of CFOs is illustrated in the chart below:
Catalyst Pharmaceutical Partners Inc. (CPRX, Financial): Vice President, Treasurer and CFO Alicia Grande Bought 20,000 Shares
Vice President, Treasurer and CFO of Catalyst Pharmaceutical Partners Inc. (CPRX) Alicia Grande bought 20,000 shares on 07/03/2012 at an average price of $0.55. Catalyst Pharmaceutical Partners Inc. is a biopharmaceutical company focused on the development and commercialization of prescription drugs for the treatment of addiction and obsessive compulsive disorders. Catalyst Pharmaceutical Partners Inc. has a market cap of $17.83 million; its shares were traded at around $0.58 with and P/S ratio of 36.46.
Catalyst Pharmaceutical Partners Inc. announced its financial results for the three month period ended March 31, 2012. The company reported a net loss of $1,089,186, or $0.04 per basic and diluted share, compared to a net loss of $1,517,136, or $0.08 per basic and diluted share, for the same period in 2011.
President and CEO, 10% Owner Patrick J. Mcenany, Vice President, Treasurer and CFO Alicia Grande, and COO Steve Miller bought shares of CPRX stock.
AspenBio Pharma Inc. (APPY, Financial): CFO Jeffrey Mcgonegal Bought 5,000 Shares
CFO of AspenBio Pharma Inc. (APPY) Jeffrey Mcgonegal bought 5,000 shares on 06/28/2012 at an average price of $1.92. AspenBio Pharma Inc. is an emerging bio-pharmaceutical company dedicated to the discovery, development, manufacture, and marketing of novel proprietary products, including those that enhance the reproductive efficiency of animals and that have large worldwide market potential. Aspenbio Pharma Inc. has a market cap of $3.03 million; its shares were traded at around $1.88 with and P/S ratio of 13.82.
President, CEO Steve Lundy, CFO Jeffrey Mcgonegal, and Vice President Gregory Pusey bought of APPY stock.
Methode Electronics Inc. (MEI, Financial): CFO Douglas A. Koman Bought 3,616 Shares
CFO of Methode Electronics Inc. (MEI) Douglas A. Koman bought 3,616 shares on 07/02/2012 at an average price of $7.95. Methode Electronics Inc. manufactures component devices world-wide for Original Equipment Manufacturers of information processing and networking equipment, voice and data communications systems, consumer electronics, automobiles, aerospace vehicles and industrial equipment. Methode Electronics Inc. has a market cap of $314.68 million; its shares were traded at around $8.5 with a P/E ratio of 35.42 and P/S ratio of 0.68. The dividend yield of Methode Electronics Inc. stocks is 3.29%.
Methode Electronics, Inc. announced financial results for the Fiscal 2012 second quarter ended October 29, 2011. Methode's second-quarter fiscal 2012 net sales increased $8.2 million, or 7.6 percent, to $115.9 million from $107.7 million in the same quarter of fiscal 2011. Translation of foreign currency increased net sales $1.0 million, or 0.8 percent, in the year-over-year comparison. Net income increased $0.8 million to $0.3 million, or $0.01 per share, in the second quarter of fiscal 2012 from a loss of $0.5 million, or $0.01 per share, in the same period of Fiscal 2011.
CEO Donald W. Duda, CFO Douglas A. Koman, and Controller and Treasurer Ronald Tsoumas bought shares of MEI stock.
MannKind Corporation (MNKD, Financial): Corporate Vice President and CFO Matthew J. Pfeffer Bought 1,054 Shares
Corporate Vice President and CFO of MannKind Corporation (MNKD) Matthew J. Pfeffer bought 1,054 shares on 06/30/2012 at an average price of $1.95. MannKind Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diseases such as diabetes, cancer, inflammatory and autoimmune diseases. MannKind Corporation has a market cap of $461.51 million; its shares were traded at around $2.74 with and P/S ratio of 9230.21.
MannKind Corporation reported financial results for the first quarter ended March 31, 2012. For the first quarter of 2012, total operating expenses were $33.9 million, compared to $38.1 million for the first quarter of 2011, a decrease of $4.1 million. Research and development (R&D) expenses were $24.2 million for the first quarter of 2012 compared to $26.3 million for the same quarter in 2011, a decrease of $2.1 million. The net loss applicable to common stockholders for the first quarter of 2012 was $38.2 million, or $0.27 per share based on 143.2 million weighted average shares outstanding, compared with a net loss applicable to common stockholders of $41.5 million, or $0.34 per share based on 121.1 million weighted average shares outstanding for the first quarter of 2011.
Corporate Vice President and CFO Matthew J. Pfeffer, 10% Owner Alfred E. Mann, and Corporate Vice President Juergen Martens bought shares of MNKD stock.
For the complete list of stocks that bought by their CFOs, go to: Insider Buys.
Catalyst Pharmaceutical Partners Inc. (CPRX, Financial): Vice President, Treasurer and CFO Alicia Grande Bought 20,000 Shares
Vice President, Treasurer and CFO of Catalyst Pharmaceutical Partners Inc. (CPRX) Alicia Grande bought 20,000 shares on 07/03/2012 at an average price of $0.55. Catalyst Pharmaceutical Partners Inc. is a biopharmaceutical company focused on the development and commercialization of prescription drugs for the treatment of addiction and obsessive compulsive disorders. Catalyst Pharmaceutical Partners Inc. has a market cap of $17.83 million; its shares were traded at around $0.58 with and P/S ratio of 36.46.
Catalyst Pharmaceutical Partners Inc. announced its financial results for the three month period ended March 31, 2012. The company reported a net loss of $1,089,186, or $0.04 per basic and diluted share, compared to a net loss of $1,517,136, or $0.08 per basic and diluted share, for the same period in 2011.
President and CEO, 10% Owner Patrick J. Mcenany, Vice President, Treasurer and CFO Alicia Grande, and COO Steve Miller bought shares of CPRX stock.
AspenBio Pharma Inc. (APPY, Financial): CFO Jeffrey Mcgonegal Bought 5,000 Shares
CFO of AspenBio Pharma Inc. (APPY) Jeffrey Mcgonegal bought 5,000 shares on 06/28/2012 at an average price of $1.92. AspenBio Pharma Inc. is an emerging bio-pharmaceutical company dedicated to the discovery, development, manufacture, and marketing of novel proprietary products, including those that enhance the reproductive efficiency of animals and that have large worldwide market potential. Aspenbio Pharma Inc. has a market cap of $3.03 million; its shares were traded at around $1.88 with and P/S ratio of 13.82.
President, CEO Steve Lundy, CFO Jeffrey Mcgonegal, and Vice President Gregory Pusey bought of APPY stock.
Methode Electronics Inc. (MEI, Financial): CFO Douglas A. Koman Bought 3,616 Shares
CFO of Methode Electronics Inc. (MEI) Douglas A. Koman bought 3,616 shares on 07/02/2012 at an average price of $7.95. Methode Electronics Inc. manufactures component devices world-wide for Original Equipment Manufacturers of information processing and networking equipment, voice and data communications systems, consumer electronics, automobiles, aerospace vehicles and industrial equipment. Methode Electronics Inc. has a market cap of $314.68 million; its shares were traded at around $8.5 with a P/E ratio of 35.42 and P/S ratio of 0.68. The dividend yield of Methode Electronics Inc. stocks is 3.29%.
Methode Electronics, Inc. announced financial results for the Fiscal 2012 second quarter ended October 29, 2011. Methode's second-quarter fiscal 2012 net sales increased $8.2 million, or 7.6 percent, to $115.9 million from $107.7 million in the same quarter of fiscal 2011. Translation of foreign currency increased net sales $1.0 million, or 0.8 percent, in the year-over-year comparison. Net income increased $0.8 million to $0.3 million, or $0.01 per share, in the second quarter of fiscal 2012 from a loss of $0.5 million, or $0.01 per share, in the same period of Fiscal 2011.
CEO Donald W. Duda, CFO Douglas A. Koman, and Controller and Treasurer Ronald Tsoumas bought shares of MEI stock.
MannKind Corporation (MNKD, Financial): Corporate Vice President and CFO Matthew J. Pfeffer Bought 1,054 Shares
Corporate Vice President and CFO of MannKind Corporation (MNKD) Matthew J. Pfeffer bought 1,054 shares on 06/30/2012 at an average price of $1.95. MannKind Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diseases such as diabetes, cancer, inflammatory and autoimmune diseases. MannKind Corporation has a market cap of $461.51 million; its shares were traded at around $2.74 with and P/S ratio of 9230.21.
MannKind Corporation reported financial results for the first quarter ended March 31, 2012. For the first quarter of 2012, total operating expenses were $33.9 million, compared to $38.1 million for the first quarter of 2011, a decrease of $4.1 million. Research and development (R&D) expenses were $24.2 million for the first quarter of 2012 compared to $26.3 million for the same quarter in 2011, a decrease of $2.1 million. The net loss applicable to common stockholders for the first quarter of 2012 was $38.2 million, or $0.27 per share based on 143.2 million weighted average shares outstanding, compared with a net loss applicable to common stockholders of $41.5 million, or $0.34 per share based on 121.1 million weighted average shares outstanding for the first quarter of 2011.
Corporate Vice President and CFO Matthew J. Pfeffer, 10% Owner Alfred E. Mann, and Corporate Vice President Juergen Martens bought shares of MNKD stock.
For the complete list of stocks that bought by their CFOs, go to: Insider Buys.
- CEO Buys, CFO Buys: Stocks that are bought by their CEO/CFOs.
- Insider Cluster Buys: Stocks that multiple company officers and directors have bought.
- Double Buys: Companies that both Gurus and Insiders are buying
- Triple Buys: Companies that both Gurus and Insiders are buying, and Company is buying back.
